


## RTC-5

<b>Cat. No.:</b>	HY-123952		
<b>CAS No.:</b>	1423077-49-9		
<b>Molecular Formula:</b>	C <sub>24</sub> H <sub>22</sub> ClF <sub>3</sub> N <sub>2</sub> O <sub>3</sub> S		
<b>Molecular Weight:</b>	510.96		
<b>Target:</b>	EGFR		
<b>Pathway:</b>	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



## SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 15 mg/mL (29.36 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	<b>Preparing Stock Solutions</b>	1 mM	1.9571 mL	9.7855 mL	19.5710 mL
		5 mM	0.3914 mL	1.9571 mL	3.9142 mL
10 mM		0.1957 mL	0.9786 mL	1.9571 mL	
Please refer to the solubility information to select the appropriate solvent.					
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 1.5 mg/mL (2.94 mM); Clear solution  2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 1.5 mg/mL (2.94 mM); Clear solution				

## BIOLOGICAL ACTIVITY

<b>Description</b>	RTC-5 (TRC-382) is an optimized phenothiazine with anti-cancer potency. RTC-5 demonstrates efficacy against a xenograft model of an EGFR driven cancer, its effects is attributed to concomitant negative regulation of PI3K-AKT and RAS-ERK signaling <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	IC50: EGFR <sup>[1]</sup>
<b>In Vitro</b>	RTC-5 (0-40 μM; 48 hours) inhibits H1650 lung adenocarcinoma cell growth with an GI <sub>50</sub> of 12.6μM <sup>[1]</sup> . RTC-5 (20-40 μM; 24 hours) negatively regulates PI3K-AKT and RAS-ERK pathways by decreasing phospho-AKT and phospho-ERK levels expression <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

#### Cell Viability Assay<sup>[1]</sup>

Cell Line:	H1650 lung adenocarcinoma cells
Concentration:	0 $\mu$ M, 1 $\mu$ M, 10 $\mu$ M, 20 $\mu$ M, 30 $\mu$ M, 40 $\mu$ M
Incubation Time:	48 hours
Result:	Inhibited H1650 lung adenocarcinoma cell growth.

#### Western Blot Analysis<sup>[1]</sup>

Cell Line:	H1650 lung adenocarcinoma cells
Concentration:	20 $\mu$ M, 40 $\mu$ M
Incubation Time:	24 hours
Result:	Decreased p-AKT, p-ERK expression.

---

## REFERENCES

[1]. Kastrinsky DB, et al. Reengineered tricyclic anti-cancer agents. *Bioorg Med Chem*. 2015 Oct 1;23(19):6528-34.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA